Investigating how gut signals affect liver function and drug metabolism
Gut-liver crosstalk by FGF15/19 in regulating xenobiotic nuclear receptor activation
This study is looking at how certain signals from the gut affect liver function and drug processing, especially for people with fatty liver disease, to help make safer medications for them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rutgers Biomedical and Health Sciences NIH-funded |
| Lab location | 1 site (Newark, UNITED STATES) |
| Project ID | NIH-10606597 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of fibroblast growth factors (FGF15/19) in regulating bile acid homeostasis and their impact on drug metabolism in the liver. By using genetically modified mouse models, the study aims to explore how these gut-derived signals influence the expression of genes involved in drug metabolism, particularly in the context of metabolism dysfunction associated fatty liver disease (MASLD) and its severe form, steatohepatitis (MASH). The findings could provide insights into safe drug development for patients suffering from these liver conditions.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with metabolism dysfunction associated fatty liver disease (MASLD) or steatohepatitis (MASH).
Not a fit: Patients with liver diseases unrelated to bile acid dysregulation or those without metabolic dysfunction may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to the development of effective and safe treatments for patients with fatty liver disease and related metabolic disorders.
How similar studies have performed: Previous research has shown promising results in understanding the role of FGF15/19 in bile acid regulation, but this specific approach to drug metabolism is relatively novel.
Where this research is happening
Newark, UNITED STATES
- Rutgers Biomedical and Health Sciences — Newark, United States (Active)
Researchers
- Principal investigator: Guo, Grace L — Rutgers Biomedical and Health Sciences
- Study coordinator: Guo, Grace L
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.